U.S. FDA’s Push to Eliminate Clinical Trials for Certain Biosimilars Is a Opportunity for Global…
The U.S. FDA has signaled a strategic shift in biosimilar development requirements. On 29 October 2025, the agency released a draft…
U.S. FDA’s Push to Eliminate Clinical Trials for Certain Biosimilars Is a Opportunity for Global Biomanufacturers
The U.S. FDA has signaled a strategic shift in biosimilar development requirements. On 29 October 2025, the agency released a draft guidance proposing that certain biosimilars may be approved without comparative clinical efficacy studies if advanced analytical comparability demonstrates a high degree of similarity to the reference biologic.
This development aligns with FDA’s position that new analytical technologies can detect clinically meaningful differences with greater sensitivity than legacy human efficacy trials.
The policy has strategic implications for global biosimilar development, but the opportunity for Indian manufacturers and sponsors using India as a development base is particularly significant.
Read more: https://resource.ddregpharma.com/insights/fda-eliminates-clinical-trials-for-biosimilars/
메타데이터
- post_id
- bb40fbd3c294
- slug
- u-s-fdas-push-to-eliminate-clinical-trials-for-certain-biosimilars-is-a-opportunity-for-global-bb40fbd3c294
- url
- https://medium.com/@ddregweb/u-s-fdas-push-to-eliminate-clinical-trials-for-certain-biosimilars-is-a-opportunity-for-global-bb40fbd3c294
- canonical_url
- https://medium.com/@ddregweb/u-s-fdas-push-to-eliminate-clinical-trials-for-certain-biosimilars-is-a-opportunity-for-global-bb40fbd3c294
- author_url
- https://medium.com/@ddregweb
- status
- ok
- fetched_at
- 2026-06-09 15:37:30
